前列腺素E1对接受重大胃肠手术患者的临床效果
该回顾性研究纳入889例因胃肠创伤、穿孔或梗阻接受重大胃肠手术的患者,经倾向评分匹配后比较PGE1组与非PGE1组的临床结局。结果显示PGE1与更快的术后胃肠功能恢复、更低的总体并发症(包括感染性并发症和重大并发症)相关,且术后第3天C反应蛋白水平更低。
要点
- PGE1与更快的术后首次排便和术后3天内首次进食相关。
- PGE1组总体并发症、感染性并发症及重大并发症发生率均更低。
- PGE1组术后第3天C反应蛋白水平更低,提示炎症反应减轻。
核心结论
- PGE1与急诊胃肠手术后更快的胃肠功能恢复和更低的总体并发症相关,可能归因于炎症反应减轻。
研究设计与样本
- 回顾性研究,纳入889例因胃肠创伤、穿孔或梗阻接受重大胃肠手术的患者,采用倾向评分匹配调整基线差异。
- 在278对匹配患者中比较了PGE1组与非PGE1组的营养、免疫和炎症指标。
主要发现
- PGE1组首次排便时间为术后2.6±0.9天,非PGE1组为3.1±1.0天(风险比0.51,95%CI 0.41-0.65,P<0.001)。
- PGE1组术后3天内首次进食179例(64.39%),非PGE1组152例(54.68%)(风险比0.61,95%CI 0.42-0.90,P=0.012)。
- PGE1组感染性并发症45例(16.2%),非PGE1组68例(24.5%)(比值比0.60,95%CI 0.39-0.91,P=0.010)。
- PGE1组重大并发症23例(8.3%),非PGE1组48例(17.3%)(比值比0.43,95%CI 0.26-0.73,P=0.001)。
- PGE1组术后第3天C反应蛋白为52.5±36.4 mg/L,非PGE1组为89.6±42.4 mg/L(P=0.037,t检验)。
临床怎么用
- 对于接受急诊胃肠手术的患者,可考虑使用PGE1以促进术后胃肠功能恢复并降低并发症风险。
局限性
- 本研究为回顾性研究,尽管采用倾向评分匹配,仍可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to investigate the clinical effects of prostaglandin E1 (PGE1) in patients who underwent surgery for gastrointestinal (GI) trauma, perforation, or obstruction. BACKGROUND: PGE1 is thought to enhance intestinal blood supply and reduce GI complications during the postoperative period. METHODS: The medical records of 889 patients undergoing major GI surgery were reviewed retrospectively. Propensity score matching was performed to adjust for any baseline differences. Clinical outcomes, including early GI function recovery, postoperative complications, and length of hospital stay, were evaluated in all patients. In 278 paired patients, selected nutritional, immunologic, and inflammatory variables were compared based on PGE1 administration. RESULTS: After propensity score 1:1 matching, the baseline characteristics were similar for both groups. PGE1 was associated with prompt postoperative GI function recovery, including first bowel movement [2.6 ± 0.9 vs 3.1 ± 1.0 days after surgery in patients with and without PGE1 treatment, risk ratio 0.51, 95% confidence interval (CI) 0.41-0.65, P < 0.001] and first feeding within postoperative day 3 [179 (64.39%) vs 152 (54.68%); risk ratio 0.61, 95% CI 0.42-0.90, P = 0.012]. A lower overall postoperative complication rate, including infectious complications [45 (16.2%) vs 68 (24.5%); odds ratio 0.60, 95% CI 0.39-0.91, P = 0.010] and major complications [23 (8.3%) vs 48 (17.3%); odds ratio 0.43, 95% CI 0.26-0.73, P = 0.001], was noted in patients with PGE1 treatment than in patients without PGE1 treatment. Furthermore, the immunologic and inflammatory variable C-reactive protein on postoperative day 3 was reduced by PGE1 treatment (52.5 ± 36.4 vs 89.6 ± 42.4 mg/L; P = 0.037, t test). CONCLUSIONS: PGE1 is associated with beneficial clinical effects, such as prompt postoperative GI function recovery and reduced overall postoperative complications after emergency GI surgery, which may be attributed to a reduced inflammatory response.
引用
- Hao F, Guo H, Zhong J, et al. Effects of Prostaglandin E1 on Patients Undergoing Major Gastrointestinal Surgery. Ann Surg. 2018. PMID: 28121679. doi:10.1097/SLA.0000000000002152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。